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Previewsmodel has other phenotypic similarities to
children with HGPS, particularly craniofa-
cial deformation, loss of subcutaneous
fat, scleroderma, and alopecia. It would
be extremely interesting to correlate
decreased Wnt signaling with some of
these abnormalities. Notably, Espada
et al. (2008) previously reported reduced
Wnt signaling in skin cells from Zmpste24
null mice, which express unprocessed,
farnesylated prelamin A and develop
a progeroid phenotype.
Hernandez et al. (2010) further demon-
strated that treatment of cultured fibro-
blasts from adult LmnaL530P/L530P mice
with a Gsk-3b inhibitor, which is known
to activate the Wnt effector protein b-cat-
enin, improved survival, and restored
proliferation. They also showed that the
inhibitor improved proliferation of cell
lines from two human subjects with
HGPS. This preliminary observation sug-
gests a potential new therapeutic option
for HGPS. Gsk-3b inhibitors were identi-
fied in the late 1990s and have been
considered for development to treat356 Developmental Cell 19, September 14, 20several diseases, including Alzheimer’s
disease, other neurodegenerative disor-
ders, bipolar affective disorder, and dia-
betes mellitus (Meijer et al., 2004). How-
ever, it is critical to see whether further
studies in animal models of HGPS show
the type of safety and efficacy that would
potentially warrant human clinical trials.
The work in this issue of Developmental
Cell provides further evidence that the
nuclear envelope functions as a critical
signaling node in development and
disease. It further confirms the power of
experimental animal models to decipher
pathogenic mechanisms and identify
potential targets for therapy. Finally, these
results in a mouse model of progeria are
compelling enough to encourage studies
of Wnt signaling in physiological aging.REFERENCES
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In a recent issue of Cell, Ohta et al. report a method of quantitative proteomics coupled with bioinformatic
analysis for the identification of associated components in complex mixtures. Using this approach, they
assayed the protein composition ofmitotic chromosomes, identifying 4029 associated proteins, 562 of which
are previously uncharacterized.The isolation of subcellular fractions and
the identification of their constituents are
instrumental to deciphering how cellular
processes work. Unlike the genome,
however, the proteome varies both tem-
porally and across cell types, making it
challenging to precisely define on a global
scale. Currently, mass spectrometry
provides the most comprehensive andversatile tool in large-scale proteomics.
Combined with classic cell biological
methods of isolation, mass spectrom-
etry-based approaches have successfully
identified hundreds of new protein com-
ponents of specific organelles and sub-
cellular structures ranging frommitochon-
dria to the spliceosome to the mitotic
spindle (Yates et al., 2005). Nevertheless,many key challenges to this approach
remain. For example, the complexity of
the spectra and proteomics data pro-
duced from tens of thousands of peptides
can easily overwhelm the available bioin-
formatics tools. Beyond this, the Achilles’
heel (and perhaps the most severe limita-
tion) of the approach is distinguishing real
constituents of a complex from simple
Figure 1. Using Multiclassifier Combinational Proteomics (MCCP) to Define Mitotic Chromosomal Proteins
Chromosome and nonchromosome samples were prepared using customized experimental procedures (gray) exploiting heavy (13C) or light (12C) amino acid
labeling. Quantitative mass spectrometry of isolated peptides (green), multidimensional combination analysis of six different classifiers (yellow), and random
forest analysis (orange) predicted chromosomal proteins (purple) that were experimentally tested (blue) using GFP fusions.
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Previewscontaminants. The purity and the integrity
of organelle preparations are frequently
mutually exclusive properties—the more
complex the structure, the more likely
that every effort to increase purity (and
remove contaminants) will cause the loss
of important but weakly associated true
components.
In a recent Resource article inCell, Ohta
et al. (2010) propose a solution to these
problems. The key to their approach is
the use of multiclassifier combinational
proteomics (MCCP) to identify functionalrelationships between proteins present
in complex mixtures. There are three key
parts to this method (Figure 1). First, the
mass spectrometry is done quantitatively
through the use of a heavy/light, stable
isotope labeling with amino acids in cell
culture (SILAC) approach (Ong et al.,
2002). Second, a set of ‘‘classifiers’’
(abundance, enrichment in the isolated
complex, the degree of ‘‘exchangeability’’
of each protein within the complex, and
any property or properties unique to the
complex being analyzed, such as theDevelopmental Cell 19, Seeffects of specific mutations) is defined.
Third, functional relationships between
proteins are uncovered through a bio-
informatics approach using what is
called a random forest analysis (Breiman,
2001), a machine learning approach for
detecting patterns in the behavior of
groups of components so as to reveal
their functional relationships and cluster
them into functionally relevant groups.
The underlying logic and application of
the random forest method will very likely
be immediately apparent only to theptember 14, 2010 ª2010 Elsevier Inc. 357
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Previewsbioinformatics expert, but for the rest of
us it is important to point out three crucial
strengths of this method. First, it enables
analysis of data sets that contain missing
values (e.g., when a protein is missing
from one of several data sets, which is
very common in mass spectrometry
analysis). Second, it can be expanded
indefinitely by adding more data sets.
Third, data can be incorporated from any
experimental approach in which the
proteins of interest are sorted systemati-
cally (e.g., data from microarrays, yeast
two-hybrid screens, systematic protein
pulldowns, protein phosphorylation and
localization). In principle, this approach
can be used to study any complex struc-
ture and may be especially useful for
dynamic organelles and structures with
transient components.
As a proof-of-principle of the power of
their multiclassifier proteomic methods,
Ohta et al. (2010) focus on the analysis
of the composition of mitotic chromo-
somes. The chromosome, a name coined
in 1888 by the anatomist HeinrichWilhelm
Gottfried von Waldeyer-Hartz, has long
been known to be a highly condensed,
organized form of chromatin that appears
as cells enter mitosis. However, its protein
composition still remains undefined de-
spite more than a century of intense
study, largely because it is virtually impos-
sible to purify large quantities of mitotic
chromosomes free of cytoplasmic
contaminants that adhere through non-
specific hydrophobic or electrostatic
interactions. In contrast to previous
smaller-scale proteomic studies ofmitotic
chromosomes (Gassmann et al., 2005;
Morrison et al., 2002; Porter et al., 2007;
Takata et al., 2007; Uchiyama et al.,
2005), Ohta et al. (2010) used large-scale
quantitative mass spectrometry to iden-
tify chromosomal proteins in the context
of intact chromosomes. Using chromo-
somes purified from chicken cells, SILAC
mass spectrometric techniques, and
follow-up bioinformatics analyses, Ohta
et al. (2010) identified 4029 mitotic chro-
mosome-associated proteins. Using six
classifiers that they defined and sub-
sequent random forest analysis, they
classified 1530 of these proteins as
‘‘hitchhikers’’—that is, nonchromosomal
proteins remaining in the chromosomal
preparation (which the authors argue are
different from conventional contaminants
in that they represent in vivo associations,358 Developmental Cell 19, September 14, 20rather than in vitro artifactual association
after cell lysis).
The key to the success of the MCCP
approach in distinguishing bona fide
protein associations from the nonspecific
is the definition of six different classifiers,
each providing an independent measure
of the association of a protein with the
complex being studied, in this case
mitotic chromosomes (Figure 1). The first
classifier—abundance—is perhaps the
most obvious. The authors determined
this value for each protein in mitotic chro-
mosomes using a standard curve pro-
duced from proteins of known abundance
and a scaled protein abundance index
based on the number of peptides ob-
served and the spectral count for each
protein. (As expected, histones scored
highly here, comprising almost half of total
chromosomal protein mass.) A second
classifier exploited the use of heavy/light
isotopic labeling of amino acids to esti-
mate the enrichment of individual proteins
in an isolated chromosomal fraction (light)
versus the amount in a cytoplasmic
extract (labeled with heavy 13C amino
acids). Classifier III measured the ability
of a protein to stably bind to (light) chro-
mosomes during an in vitro incubation in
a (heavy) cytosolic supernatant. Classifier
IV exploited differences in chromosome
composition that follow from the loss
of a component that is a key player in
mitotic chromosome condensation and
structural integrity. Using a conditional
deletion of the condensin subunit SMC2,
correctly condensed chromosomes from
SMC2-containing (light labeled) cells
were mixed with samples from SMC2-
depleted (heavy labeled) cells, and the
relative abundance of each protein was
determined by the heavy/light ratios. To
focus on centromere proteins and those
associated with the spindle microtubule-
binding kinetochore that assembles onto
the centromere early in mitosis, classifier
V was modeled after classifier IV except
with a focus on the chromosomal abun-
dance of each protein after deletion of
the nonessential kinetochore component
Ska3/Rama1. Finally, classifier VI was
defined by performing bioinformatic
analysis on the domains in each protein
of interest, as a means of identifying
chromosomal proteins by the presence of
domains more frequently found in known
chromosome-bound proteins than cyto-
solic proteins.10 ª2010 Elsevier Inc.Each classifier on its own lacks a clear
boundary between bona fide chromo-
somal proteins and cytosolic proteins,
but the strength in the MCCP approach
comes from the combination of different
classifiers and random forest analysis to
allow for simultaneous integration of the
information present in all of the proteo-
mics classifiers. Indeed, the combined
proteomic classifiers assigned 118 of
125 known centromere proteins correctly
as chromosomal, a 94.4% success rate.
Of the 4029 chromosomal proteins iden-
tified, 562 were previously uncharacter-
ized. To validate the strength of the
prediction that these are indeed chromo-
somal proteins, the authors analyzed the
localization of 50 of these uncharacterized
proteins tagged with GFP and showed
that 88% localized as predicted. In addi-
tion, this analysis demonstrated that 13
of these 50 newly cloned proteins are
associated with kinetochores in mitosis,
thus expanding the list of known centro-
mere proteins beyond CENP-Z up to
CENP-36. Among these, the authors
further characterized CENP-32, showing
that its reduction by siRNA disrupted
spindle morphology and chromosome
alignment. Perhaps most provocatively,
the analysis predicts that 97 more centro-
mere proteins remain to be discovered in
the pool of the 510 remaining uncharac-
terized chromosomal proteins uncovered
in the current study. Identification of these
proteins and characterization of their role
in the structure and function of the
centromere will serve as a starting point
for in-depth systematic analysis of mech-
anisms involved in mitotic chromosome
segregation.
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The dosage of X and Y chromosome genes varies systematically in males and females. In mammals, X inac-
tivation largely compensates for this, but in this issue of Developmental Cell, Wijchers et al. show that the
expression of hundreds of autosomal genes is still influenced by sex chromosome dosage, independently
of physiological sex.Unlike the other chromosomes in the
mammalian genomic complement, the X
and Y chromosomes are expected to do
different things in roughly half of all indi-
viduals. The Y chromosome may or may
not be present and the X may be present
in one or two copies, in which case one
of the two is inactivated. Given such
a systematic variation in a substantial
part of the genome, an obvious question
is whether the expression of autosomal
genes might be affected. In fact, this
was the basis for a theory of gene balance
and sex chromosome dosage compensa-
tion (Birchler et al., 2001). According to
this, the dosage of genes encoding tran-
scriptional regulators, most of which act
as repressors, has broad inverse effects
on the expression of other genes. In prin-
ciple, X chromosome dosage compensa-
tion should equalize this kind of effect of X
chromosome gene dosage. However,
a paper by Wijchers et al. (2010), in this
issue, finds that the expression of a large
cohort of genes is in fact influenced by
the dosage of the X chromosome irre-
spective of physiological sex. Previous
analyses had shown that the expression
of thousands of genes is sexually dimor-
phic in different mouse tissues, but the
present paper distinguishes the role of
sex chromosome dosage from that of
physiological sex.
Wijchers et al. (2010) began with the
study of heterochromatic inactivation ofa transgenic hCD2 gene. When inserted
in a heterochromatic location on mouse
chromosome 18, hCD2 tends to become
inactivated in a large fraction of peripheral
T lymphocytes in a way dependent on
heterochromatic proteins such as HP1
(Festenstein et al., 1999). Surprisingly,
however, the fraction is higher in males
than in females. To distinguish the contri-
bution of the X, the Y, and physiological
sex, the authors used a set of mouse
strains in which the sex chromosome
complement can be varied without affect-
ing sex by means of a Y lacking the male-
specifying sry gene (Y) and supplying
the sex-determining Sry function by an
autosomal transgenic copy. The results
showed that it is chromosome dosage,
not sex, that is involved: XX females and
XXsry males silenced the transgene less
than XY females or XY sry males.
Furthermore, X dosage rather than the
presence of Y is the relevant factor:
XXY* males (in which the Y chromosome
is attached to an X) silence more than X0
females.
To ask if X dosage affects genome-
wide gene activity beyond heterochro-
matic variegation, Wijchers et al. (2010)
used expression microarrays. They found
that 369 autosomal genes change
expression level by a factor of 1.2 or
more when X dosage is changed, inde-
pendent of sex (comparing XYsry versus
XXsry males and XY versus XX females).In general, the differential is relatively
small, but the fact that it affects 369 genes
(and many more by a < 1.2-fold effect)
means that it could have significant
consequences.
The analysis of the progeny of these
crosses revealed two different effects:
one, due either to a double dose of X or
to the absence of Y, appears to reduce
expression of these genes (more expres-
sion in XY females than in XX females);
the other, due to Sry function, is mani-
fested only in the presence of a single X
andmore than compensates for the differ-
ences due to chromosome dosage (more
expression in XY females than in XYsry
males but also more in XXsry males than
in XYsry males).
This effect is apparently in the opposite
direction from that seen on heterochro-
matic silencing, where XX increases
expression of the heterochromatic trans-
gene. Are the two effects unrelated?
Although the explanation is not yet clear,
it appears that the two effects are likely to
be related.Like theheterochromaticeffect,
the sex chromosome dosage-dependent
genesare also sensitive to the level ofHP1.
What kind of mechanism could account
for the effect of chromosome dosage? Is it
the resultant effect of a large number of
small contributions by many genes or,
like the Sry contribution, primarily due
to one specific mechanism? Wijchers
et al. (2010) propose two possibilities.ptember 14, 2010 ª2010 Elsevier Inc. 359
